Nearly ten API enterprises to increase capital to expand production, clear this layout direction.

"Pharmaceutical Network Market Analysis" Not long ago, film giant Kodak transformed the pharmaceutical industry into the API market news caused concern in the industry.
actually this year, due to the rising business climate of the API industry, the hundreds of billions of dollars market led to a large number of "outsider" enterprises are also scrambling to lay out.
The global API market will grow to US$186.4 billion by 2020, an increase of more than 6%, according to the China Business Research Institute.
On the domestic situation, with the important position of API, the market competition is also intensified, according to statistics, from the beginning of this year, there have been nearly 10 API enterprises to increase capital to expand production, including Shi Iv Pharmaceutical Group, Hunan Jingfeng Pharmaceuticals, Fuxiang Pharmaceuticals, Aoxiang Pharmaceuticals, Aung Likang and other enterprises.
Nearly 10 API companies increased their capital to expand production on July 29, Shisi Pharmaceutical Group revealed that the company is considering the possibility of its API and medical materials integration platform split and Chinese mainland an accredited stock exchange independent listing.
the possible spin-off will continue, it will be implemented through a spin-off listing in accordance with the 15 application guidelines of the Securities Listing Rules of the Stock Exchange of Hong Kong Limited.
July 28, Hunan Jingfeng Pharmaceuticals announced that it was considering a framework agreement for cooperation in the construction of the Changde International Industrial Park Project of RAW Materials and Preparations through an investment of 282 million yuan in Changde Economic Development Zone and Deyuan Investment in Changde City, Hunan Province.
, it is learned that the total investment amount of this construction project is about 684 million yuan, this investment is aimed at integrating raw materials production resources, improve the production chain, accelerate the company's development in the field of preparations.
Earlier this year, Fuxiang Pharmaceuticals plans to raise a total of no more than 1,064 million yuan, after deducting the issuance costs will be used for high-efficiency Pernam antibiotic construction projects, an annual output of 616 tons of Nave intermediate project, the former belongs to the antibiotic category products, the latter is the antiviral category products.
Aoxiang Pharmaceuticals plans to raise no more than 350 million yuan for the construction of production bases for specialty API and key pharmaceutical intermediates.
In addition, Both Ong Likang and Guangshengtang plan to raise funds in the non-public offering of about 500 million yuan, of which, Anlikang plans to produce 5 tons of dosso tea base, 20 tons of potassium hydroxide and other raw materials projects;
"API and preparation integration" into an important layout direction from the more than a dozen enterprises to increase capital to expand production action, it can be seen that the technology and production conditions with API has become the layout direction of many large pharmaceutical enterprises.
, Haizheng Pharmaceuticals also said on the interactive platform, to promote the company's transformation to an innovative pharmaceutical enterprise with a joint innovation, preparation and API integration.
the industry believes that with the national consistency evaluation, correlation review, with the purchase of pharmaceutical policy reform in-depth promotion, as well as domestic environmental protection policies tightening and global drug quality standards, with research and development, scale and product advantages of the "API and preparation integration" enterprises are expected to get more opportunities.
from the 2019 performance reports of various API companies, by the "API plus preparations" two-wheeled linkage of enterprises have achieved good results.
E.g., with corticosteroids and amino acid drugs as the core of the "API and preparations" industry chain leading enterprises Tian medicine shares, its 2019 annual report shows that during the reporting period, the company achieved a total operating income of 2,916 million yuan, up 20.14% YoY;
addition, the main business for the development, production and sale of steroidal RAW drugs and preparations of Xianxian Pharmaceuticals, its 2019 net profit of 410 million, an increase of 36.17 percent year-on-year.
.